Starling Oncology, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Starling Oncology, Inc. (DFPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $276.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-12
- Starling Oncology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $276.00K, a 94.58% decline from fiscal 2024.
- Starling Oncology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $5.09M, a 158.63% increase from fiscal 2023.
- Starling Oncology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $1.97M, a 39.62% increase from fiscal 2022.
- Starling Oncology, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $1.41M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $276.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $5.09M 10-K · filed 2026-03-12 |
| 2023-12-31 | $1.97M 10-K · filed 2025-03-26 |
| 2022-12-31 | $1.41M 10-K · filed 2024-03-28 |
| 2021-12-31 | -$122.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 |